183 related articles for article (PubMed ID: 29340112)
1. Incidence and relative risk of peripheral neuropathy in cancer patients treated with eribulin: a meta-analysis.
Peng L; Hong Y; Ye X; Shi P; Zhang J; Wang Y; Zhao Q
Oncotarget; 2017 Dec; 8(67):112076-112084. PubMed ID: 29340112
[TBL] [Abstract][Full Text] [Related]
2. Incidence and clinical parameters associated with eribulin mesylate-induced peripheral neuropathy.
Zhao B; Zhao H; Zhao J
Crit Rev Oncol Hematol; 2018 Aug; 128():110-117. PubMed ID: 29958626
[TBL] [Abstract][Full Text] [Related]
3. Meta-analysis of incidence and risk of peripheral neuropathy associated with intravenous bortezomib.
Peng L; Ye X; Zhou Y; Zhang J; Zhao Q
Support Care Cancer; 2015 Sep; 23(9):2813-24. PubMed ID: 25676487
[TBL] [Abstract][Full Text] [Related]
4. Incidence and risk of peripheral neuropathy with nab-paclitaxel in patients with cancer: a meta-analysis.
Peng L; Bu Z; Ye X; Zhou Y; Zhao Q
Eur J Cancer Care (Engl); 2017 Sep; 26(5):. PubMed ID: 26537178
[TBL] [Abstract][Full Text] [Related]
5. Incidence of peripheral neuropathy associated with eribulin mesylate versus vinorelbine in patients with metastatic breast cancer: sub-group analysis of a randomized phase III study.
Wu Y; Wang Q; Zhang J; Cao J; Wang B; Hu X
Support Care Cancer; 2020 Aug; 28(8):3819-3829. PubMed ID: 31832821
[TBL] [Abstract][Full Text] [Related]
6. Incidence and risk of proteinuria with aflibercept in cancer patients: a meta-analysis.
Peng L; Zhao Q; Ye X; Zhou Y; Hu D; Zheng S
PLoS One; 2014; 9(11):e111839. PubMed ID: 25365378
[TBL] [Abstract][Full Text] [Related]
7. Eribulin mesylate versus ixabepilone in patients with metastatic breast cancer: a randomized Phase II study comparing the incidence of peripheral neuropathy.
Vahdat LT; Garcia AA; Vogel C; Pellegrino C; Lindquist DL; Iannotti N; Gopalakrishna P; Sparano JA
Breast Cancer Res Treat; 2013 Jul; 140(2):341-51. PubMed ID: 23877339
[TBL] [Abstract][Full Text] [Related]
8. Comparative effectiveness and safety of eribulin in advanced or metastatic breast cancer: a systematic review and meta-analysis.
Tanni KA; Truong CB; Johnson BS; Qian J
Crit Rev Oncol Hematol; 2021 Jul; 163():103375. PubMed ID: 34087344
[TBL] [Abstract][Full Text] [Related]
9. Risk of fatigue and anemia in patients with advanced cancer treated with olaparib: A meta-analysis of randomized controlled trials.
Ruiz-Schutz VC; Gomes LM; Mariano RC; de Almeida DVP; Pimenta JM; Dal Molin GZ; Kater FR; Yamamura R; Correa Neto NF; Maluf FC; Schutz FA
Crit Rev Oncol Hematol; 2019 Sep; 141():163-173. PubMed ID: 31306986
[TBL] [Abstract][Full Text] [Related]
10. Chemotherapy-induced peripheral neuropathy in breast cancer patients treated with eribulin: interim data from a post-marketing observational study.
Tsurutani J; Sakata Y; Matsuoka T
Breast Cancer; 2019 Mar; 26(2):235-243. PubMed ID: 30324551
[TBL] [Abstract][Full Text] [Related]
11. Eribulin: a novel cytotoxic chemotherapy agent.
Preston JN; Trivedi MV
Ann Pharmacother; 2012 Jun; 46(6):802-11. PubMed ID: 22619477
[TBL] [Abstract][Full Text] [Related]
12. Hematologic toxicities in cancer patients treated with the multi-tyrosine kinase sorafenib: a meta-analysis of clinical trials.
Schutz FA; Je Y; Choueiri TK
Crit Rev Oncol Hematol; 2011 Nov; 80(2):291-300. PubMed ID: 21339073
[TBL] [Abstract][Full Text] [Related]
13. Incidence and risk of rash to mTOR inhibitors in cancer patients--a meta-analysis of randomized controlled trials.
Shameem R; Lacouture M; Wu S
Acta Oncol; 2015 Jan; 54(1):124-32. PubMed ID: 24914484
[TBL] [Abstract][Full Text] [Related]
14. Risk of hematologic toxicities in cancer patients treated with sunitinib: a systematic review and meta-analysis.
Funakoshi T; Latif A; Galsky MD
Cancer Treat Rev; 2013 Nov; 39(7):818-30. PubMed ID: 23455076
[TBL] [Abstract][Full Text] [Related]
15. Eribulin mesylate, a novel microtubule inhibitor in the treatment of breast cancer.
Cortes J; Montero AJ; Glück S
Cancer Treat Rev; 2012 Apr; 38(2):143-51. PubMed ID: 21550727
[TBL] [Abstract][Full Text] [Related]
16. Incidence and risk of high-grade stomatitis with mTOR inhibitors in cancer patients.
Shameem R; Lacouture M; Wu S
Cancer Invest; 2015 Mar; 33(3):70-7. PubMed ID: 25635371
[TBL] [Abstract][Full Text] [Related]
17. Risk of anemia attributable to everolimus in patients with cancer: a meta-analysis of randomized controlled trials.
Shameem R; Hamid MS; Wu S
Anticancer Res; 2015 Apr; 35(4):2333-40. PubMed ID: 25862897
[TBL] [Abstract][Full Text] [Related]
18. Incidence and risk of hypertension associated with ramucirumab in cancer patients: A systematic review and meta-analysis.
Qi WX; Fu S; Zhang Q; Guo XM
J Cancer Res Ther; 2016; 12(2):775-81. PubMed ID: 27461650
[TBL] [Abstract][Full Text] [Related]
19. Treatment-related fatigue with everolimus and temsirolimus in patients with cancer-a meta-analysis of clinical trials.
Peng L; Zhou Y; Ye X; Zhao Q
Tumour Biol; 2015 Feb; 36(2):643-54. PubMed ID: 25281033
[TBL] [Abstract][Full Text] [Related]
20. Incidence and relative risk of cutaneous squamous cell carcinoma with single-agent BRAF inhibitor and dual BRAF/MEK inhibitors in cancer patients: a meta-analysis.
Peng L; Wang Y; Hong Y; Ye X; Shi P; Zhang J; Zhao Q
Oncotarget; 2017 Oct; 8(47):83280-83291. PubMed ID: 29137342
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
